The contract adds a new revenue stream, but the contingent portion depends on SAB-142's clinical and regulatory success. Monitor SAB-142 trial updates and milestone announcements for revenue recognition triggers.
EBS drugs
EBS drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $7.99entry
- T+1 · 7mo ago +3.00%α +1.98% · $8.23
- T+5 · 7mo ago +13.89%α +10.78% · $9.10
- T+20 · 6mo ago +14.89%α +8.85% · $9.18
- T+60 · 4mo ago −9.14%α −13.25% · $7.26
Price Chart
How similar events traded
Executive Summary
Emergent BioSolutions announced a multi-year agreement with SAB Biotherapeutics to provide manufacturing services for SAB-142, a clinical-stage treatment for type 1 diabetes. The deal is valued at approximately $50 million, with $36 million contingent on regulatory milestones, providing moderate revenue upside for EBS.
Key Financial Metrics
Key Facts
- Emergent BioSolutions signs multi-year manufacturing agreement with SAB Biotherapeutics
- Agreement valued at ~$50 million, with $36 million contingent on regulatory approval and milestones
- Services include process development, scale-up, and manufacturing for SAB-142, a T1D treatment
- Manufacturing to take place at Emergent's Winnipeg facility
Financial Impact
Approximately $14 million in near-term revenue (guaranteed portion) with potential total of $50 million if all milestones met
Risk Factors
- Only $14M is guaranteed; $36M contingent on regulatory approval and milestones
- SAB-142 is in clinical development; risk of trial failure or regulatory delay
- Manufacturing contracts may have lower margins than proprietary products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283664 |
Track record
23 reports on EBS
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.87% at T+60 after the Apr 16, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
- Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
- Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers